Advanced Drug Delivery Reviews

Article	Citations
Liposome composition in drug delivery design, synthesis, characterization, and clinical application	411
The role of lipid components in lipid nanoparticles for vaccines and gene therapy	339
Self-assembled mRNA vaccines	301
COVID-19 vaccines: The status and perspectives in delivery points of view	259
To PEGylate or not to PEGylate: Immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives	234
Supramolecular engineering of hydrogels for drug delivery	215
Pharmaceutical electrospinning and 3D printing scaffold design for bone regeneration	204
Overcoming barriers by local drug delivery with liposomes	201
DNA hydrogel-based gene editing and drug delivery systems	195
RNAi-based therapeutics and tumor targeted delivery in cancer	188
Recombinant protein vaccines, a proven approach against coronavirus pandemics	185
Dosing extracellular vesicles	181
Translating 3D printed pharmaceuticals: From hype to real-world clinical applications	174
Nucleic acid delivery for therapeutic applications	161
Non-viral COVID-19 vaccine delivery systems	160
Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers	160
Connected healthcare: Improving patient care using digital health technologies	160
Fibronectin in development and wound healing	157
Frontiers in the treatment of glioblastoma: Past, present and emerging	150
Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis	147
Advances in powder bed fusion 3D printing in drug delivery and healthcare	145
Recent advances in design of antimicrobial peptides and polypeptides toward clinical translation	145
Peptide and peptide-based inhibitors of SARS-CoV-2 entry	139
Nanoscale MOFs: From synthesis to drug delivery and theranostics applications	138
Machine learning directed drug formulation development	135

Clinical translation of nanomedicines: Challenges, opportunities, and keys	134
Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies	132
Rational designs of in vivo CRISPR-Cas delivery systems	131
Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy	131
Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment	129
Advanced engineered nanoparticulate platforms to address key biological barriers for delivering chemotherapeutic agents to target sites	126
Opening doors with ultrasound and microbubbles: Beating biological barriers to promote drug delivery	126
The tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives	123
Antimicrobial peptides towards clinical application: Delivery and formulation	122
Peptide-based supramolecular hydrogels for local drug delivery	117
Approaches to surface engineering of extracellular vesicles	116
Engineering the drug carrier biointerface to overcome biological barriers to drug delivery	116
Technology insight: Plant-derived vesicles—How far from the clinical biotherapeutics and therapeutic drug carriers?	115
(Macro)molecular self-assembly for hydrogel drug delivery	113
Emerging 3D printing technologies for drug delivery devices: Current status and future perspective	113
Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment	109
Polymeric drug delivery systems by additive manufacturing	109
Topical drug delivery: History, percutaneous absorption, and product development	107
Extracellular vesicles as a drug delivery system: A systematic review of preclinical studies	106
Targeting drug delivery with light: A highly focused approach	105
Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge	100
Extracellular vesicles for tissue repair and regeneration: Evidence, challenges and opportunities	99
The effects of protein corona on in vivo fate of nanocarriers	98
Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants	97
Oral delivery of natural active small molecules by polymeric nanoparticles for the treatment of inflammatory bowel diseases	96
Delivery of STING agonists for adjuvanting subunit vaccines	96
Near-infrared fluorescence imaging in immunotherapy	95
Harnessing artificial intelligence for the next generation of 3D printed medicines	95
Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis	95
Biomedical engineering of two-dimensional MXenes	94
Challenges of fused deposition modeling 3D printing in pharmaceutical applications: Where are we now?	94
Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms	93
Why nanoparticles prefer liver macrophage cell uptake in vivo	92
Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network	92
Mesoporous silica nanoparticles for pulmonary drug delivery	90
Traditional herbal medicine and nanomedicine: Converging disciplines to improve therapeutic efficacy and human health	90
Microneedle-Mediated Vaccination: Innovation and Translation	90
An overview of in vitro, ex vivo and in vivo models for studying the transport of drugs across intestinal barriers	89
Vaccine delivery systems toward lymph nodes	89
Coupling hot melt extrusion and fused deposition modeling: Critical properties for successful performance	88
Clinically established biodegradable long acting injectables: An industry perspective	88
Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic	87
Photodynamic and antibiotic therapy in combination against bacterial infections: efficacy, determinants, mechanisms, and future perspectives	86
Technological advances towards extracellular vesicles mass production	85
Biomembrane-based nanostructures for cancer targeting and therapy: From synthetic liposomes to natural biomembranes and membrane-vesicles	85
Let’s talk about sex: Differences in drug therapy in males and females	85
Tumor-activated carrier-free prodrug nanoparticles for targeted cancer Immunotherapy: Preclinical evidence for safe and effective drug delivery	84
Polymer- and lipid-based nanocarriers for ocular drug delivery: Current status and future perspectives	84
Target specific tight junction modulators	82
The past, present, and future of breast cancer models for nanomedicine development	80

Multifaceted role of phyto-derived polyphenols in nanodrug delivery systems	80
3D printing as a transformative tool for microneedle systems: Recent advances, manufacturing considerations and market potential	80
Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis	79
Emerging innate biological properties of nano-drug delivery systems: A focus on PAMAM dendrimers and their clinical potential	79
A call for the standardised reporting of factors affecting the exogenous loading of extracellular vesicles with therapeutic cargos	78
The in vivo fate of polymeric micelles	78
Nanomedicine for brain cancer	78
Targeting the blood-brain barrier for the delivery of stroke therapies	77
Imaging technology of the lymphatic system	77
Engineering interferons and interleukins for cancer immunotherapy	76
Novel antimicrobial agents for combating antibiotic-resistant bacteria	75
Stealth and pseudo-stealth nanocarriers	75
Nanocarrier vaccines for SARS-CoV-2	75
Advances in gene-based vaccine platforms to address the COVID-19 pandemic	75
Bacterial extracellular vesicles: Understanding biology promotes applications as nanopharmaceuticals	74
Ultrasound and microbubbles to beat barriers in tumors: Improving delivery of nanomedicine	74
Dawn of lipid nanoparticles in lymph node targeting: Potential in cancer immunotherapy	74
Shape memory materials and 4D printing in pharmaceutics	73
Separation, characterization, and standardization of extracellular vesicles for drug delivery applications	73
SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?	73
Non-spherical micro- and nanoparticles for drug delivery: Progress over 15 years	72
Exploring interactions between extracellular vesicles and cells for innovative drug delivery system design	71
Polymeric nano- and microparticulate drug delivery systems for treatment of biofilms	71
Clinical translation of advanced colonic drug delivery technologies	71
Scaled preparation of extracellular vesicles from conditioned media	71
In situ activation of therapeutics through bioorthogonal catalysis	70
Advancing pharmacy and healthcare with virtual digital technologies	70
2D materials-based nanomedicine: From discovery to applications	70
Oral nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome	69
Cancer-associated fibroblasts: Origin, function, imaging, and therapeutic targeting	69
Pharmaceutical applications of powder-based binder jet 3D printing process – A review	69
Tumor microenvironment-responsive dynamic inorganic nanoassemblies for cancer imaging and treatment	69
Cell-penetrating peptides in protein mimicry and cancer therapeutics	69
Multifunctional nanotheranostics for near infrared optical imaging-guided treatment of brain tumors	69
Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across	68
High-throughput proteomics and AI for cancer biomarker discovery	68
Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities	68
Extrahepatic targeting of lipid nanoparticles in vivo with intracellular targeting for future nanomedicines	68
Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models	68
Defensins: The natural peptide antibiotic	68
Stabilizers and their interaction with formulation components in frozen and freeze-dried protein formulations	67
Decorated bacteria and the application in drug delivery	67
Tumor-on-chip modeling of organ-specific cancer and metastasis	67
Advances in mRNA non-viral delivery approaches	67
Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy	66
Smart gating porous particles as new carriers for drug delivery	66
Nanomaterials and nanomaterials-based drug delivery to promote cutaneous wound healing	66
α-Amino acid N-carboxyanhydride (NCA)-derived synthetic polypeptides for nucleic acids delivery	66
Nucleic acid delivery with extracellular vesicles	64
Metal-organic frameworks for therapeutic gas delivery	64
Polymeric long-acting drug delivery systems (LADDS) for treatment of chronic diseases: Inserts, patches, wafers, and implants	64
The promising interplay between sonodynamic therapy and nanomedicine	63
Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood–brain barrier (BBB) to manage neurological disorders	63
Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection	63
Therapeutic targeting of the oncogenic Wnt signaling pathway for treating colorectal cancer and other colonic disorders	62
Self-assembly of protein-polymer conjugates for drug delivery	62
Dry powder pharmaceutical biologics for inhalation therapy	60
Nanovaccines with cell-derived components for cancer immunotherapy	60
Responsive optical probes for deep-tissue imaging: Photoacoustics and second near-infrared fluorescence	60
Automation and data-driven design of polymer therapeutics	60
Exosomes as natural delivery carriers for programmable therapeutic nucleic acid nanoparticles (NANPs)	59
Towards controlled drug delivery in brain tumors with microbubble-enhanced focused ultrasound	59
Extracellular vesicles as delivery systems at nano-/micro-scale	59
Cell-based drug delivery systems and their in vivo fate	59
Magnetic iron oxide nanoparticles for brain imaging and drug delivery	58
Overcoming the rising incidence and evolving mechanisms of antibiotic resistance by novel drug delivery approaches – An overview	58
Tumor microenvironment remodeling-based penetration strategies to amplify nanodrug accessibility to tumor parenchyma	58
Extracellular vesicles as antigen carriers for novel vaccination avenues	58
Stability of lyophilized and spray dried vaccine formulations	57
Bioinspired drug delivery strategies for repurposing conventional antibiotics against intracellular infections	57
Nano-delivery to the lung - by inhalation or other routes and why nano when micro is largely sufficient?	57
Nanotechnology-empowered vaccine delivery for enhancing CD8+ T cells-mediated cellular immunity	57
Optimizing synthetic nucleic acid and protein nanocarriers: The chemical evolution approach	57
Listening to drug delivery and responses via photoacoustic imaging	56
Electroactive material-based biosensors for detection and drug delivery	56
In silico T cell epitope identification for SARS-CoV-2: Progress and perspectives	56
A quantitative view on multivalent nanomedicine targeting	56
Luminescent quantum dots: Synthesis, optical properties, bioimaging and toxicity	56
A review of emerging technologies enabling improved solid oral dosage form manufacturing and processing	55
Role of CFD based in silico modelling in establishing an in vitro-in vivo correlation of aerosol deposition in the respiratory tract	55

Rationally designed drug delivery systems for the local treatment of resected glioblastoma	55
Development of extracellular vesicle-based medicinal products: A position paper of the group “Extracellular Vesicle translatiOn to clinicaL perspectiVEs – EVOLVE France”	54
Emerging strategies in developing multifunctional nanomaterials for cancer nanotheranostics	54
Applications of focused ultrasound-mediated blood-brain barrier opening	54
Artificial intelligence to bring nanomedicine to life	54
Autophagy in the cancer-immunity dialogue	54
Gene- and RNAi-activated scaffolds for bone tissue engineering: Current progress and future directions	53
Recent advances in long-acting drug delivery systems for anticancer drug	53
Red blood cells: The metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers	53
Ultrasound-mediated blood–brain barrier opening: An effective drug delivery system for theranostics of brain diseases	52
Advances and future perspectives in epithelial drug delivery	52
Activatable fluorescent probes for real-time imaging-guided tumor therapy	52
Engineering of stimuli-responsive self-assembled biomimetic nanoparticles	52
Development and aging of the lymphatic vascular system	52
Integration of personalized drug delivery systems into digital health	52
Delivering more for less: nanosized, minimal-carrier and pharmacoactive drug delivery systems	52
The RNA-binding protein HuR in human cancer: A friend or foe?	51
Advances of nanomedicines in breast cancer metastasis treatment targeting different metastatic stages	51
Human skin equivalents: Impaired barrier function in relation to the lipid and protein properties of the stratum corneum	51
Synthetic multi-layer nanoparticles for CRISPR-Cas9 genome editing	51
Targeting the tumor biophysical microenvironment to reduce resistance to immunotherapy	51
Multifunctional plasmonic-magnetic nanoparticles for bioimaging and hyperthermia	50
Organ-on-a-chip technology for the study of the female reproductive system	50
Bacterial membrane vesicles for vaccine applications	50
Modulating the foreign body response of implants for diabetes treatment	50
Mechanisms of immune response to inorganic nanoparticles and their degradation products	50
GO-based antibacterial composites: Application and design strategies	50
Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment	50
Two-Dimensional Nanomaterial-based catalytic Medicine: Theories, advanced catalyst and system design	50
Light-triggered photodynamic nanomedicines for overcoming localized therapeutic efficacy in cancer treatment	50
Recent advances in chemical modifications of guide RNA, mRNA and donor template for CRISPR-mediated genome editing	49
Microarray patches enable the development of skin-targeted vaccines against COVID-19	49
Microarray patches: Breaking down the barriers to contraceptive care and HIV prevention for women across the globe	49
Progress of engineered bacteria for tumor therapy	49
Building three-dimensional lung models for studying pharmacokinetics of inhaled drugs	49
Formulation strategies to improve the efficacy of intestinal permeation enhancers,	48
Role of extracellular vesicles in liver diseases and their therapeutic potential	48
Ferritin nanocage: A promising and designable multi-module platform for constructing dynamic nanoassembly-based drug nanocarrier	48
Adherence to minimal experimental requirements for defining extracellular vesicles and their functions	48
Novel drug delivery systems for the management of dry eye	48
Medical devices, smart drug delivery, wearables and technology for the treatment of Diabetes Mellitus	47
Self-assembling peptides as vectors for local drug delivery and tissue engineering applications	47
Nanoparticle biodistribution coefficients: A quantitative approach for understanding the tissue distribution of nanoparticles	47
The role of microneedle arrays in drug delivery and patient monitoring to prevent diabetes induced fibrosis	47
Supercritical fluid (SCF)-assisted fabrication of carrier-free drugs: An eco-friendly welcome to active pharmaceutical ingredients (APIs)	47
Drug development of lyso-thermosensitive liposomal doxorubicin: Combining hyperthermia and thermosensitive drug delivery	47
Antifibrotic strategies for medical devices	46
Antimicrobial blue light: A ‘Magic Bullet’ for the 21st century and beyond?	46
Sustained delivery approaches to improving adaptive immune responses	46
Advances in the treatment of inflammatory bowel disease: Focus on polysaccharide nanoparticulate drug delivery systems	46
Biomimetic immunomodulation strategies for effective tissue repair and restoration	45
Toward closed-loop drug delivery: Integrating wearable technologies with transdermal drug delivery systems	45
Harnessing cerebrospinal fluid circulation for drug delivery to brain tissues	45
Artificial intelligence and machine learning assisted drug delivery for effective treatment of infectious diseases	45
Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies	45
Mastering the Gram-negative bacterial barrier – Chemical approaches to increase bacterial bioavailability of antibiotics	45
Biodistribution, pharmacokinetics and excretion studies of intravenously injected nanoparticles and extracellular vesicles: Possibilities and challenges	45
Recent progress in NIR-II fluorescence imaging-guided drug delivery for cancer theranostics	45
Stimuli-responsive drug delivery systems triggered by intracellular or subcellular microenvironments	45
Understanding molecular mechanisms of biologics drug delivery and stability from NMR spectroscopy	45
Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications	44
Engineered bacterial membrane vesicles are promising carriers for vaccine design and tumor immunotherapy	44
Advances on erythrocyte-mimicking nanovehicles to overcome barriers in biological microenvironments	44
Biomaterial-based delivery of nucleic acids for tissue regeneration	44
Immunocompetent cancer-on-chip models to assess immuno-oncology therapy	44
Bacteria and bacterial derivatives as delivery carriers for immunotherapy	44
In vitro and ex vivo models in inhalation biopharmaceutical research — advances, challenges and future perspectives	44
Biosafety of mesoporous silica nanoparticles; towards clinical translation	44
Drug release from in situ forming implants and advances in release testing	44
Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic/pharmacodynamic (PK/PD) models	44
Jet injectors: Perspectives for small volume delivery with lasers	44
Nucleic acid nanoparticles (NANPs) as molecular tools to direct desirable and avoid undesirable immunological effects	43
Controlling drug release with additive manufacturing-based solutions	43
Extracellular vesicles for the treatment of central nervous system diseases	43
Two-dimensional nanomaterials for tumor microenvironment modulation and anticancer therapy	43
Emerging targeted drug delivery strategies toward ovarian cancer	42
Strategies to overcome/penetrate the BBB for systemic nanoparticle delivery to the brain/brain tumor	42
Protein corona: Friend or foe? Co-opting serum proteins for nanoparticle delivery	42
Non-viral nanoparticles for RNA interference: Principles of design and practical guidelines	42
Dynamic nanoassemblies of nanomaterials for cancer photomedicine	42
Pulmonary delivery nanomedicines towards circumventing physiological barriers: Strategies and characterization approaches	42
Nanotechnologies for the delivery of biologicals: Historical perspective and current landscape	42
Phototheranostics for multifunctional treatment of cancer with fluorescence imaging	42
Versatility on demand – The case for semi-solid micro-extrusion in pharmaceutics	42
Polymers in pharmaceutical additive manufacturing: A balancing act between printability and product performance	42
Inhalation delivery technology for genome-editing of respiratory diseases	41
Additive manufacturing in drug delivery: Innovative drug product design and opportunities for industrial application	41
The 10th anniversary of MXenes: Challenges and prospects for their surface modification toward future biotechnological applications	41
Can microorganisms develop resistance against light based anti-infective agents?	41
Pharmaceutical protein solids: Drying technology, solid-state characterization and stability	41
Coiled coil-based therapeutics and drug delivery systems	41
Nanoarchitectured two-dimensional layered double hydroxides-based nanocomposites for biomedical applications	41
Enhancing therapeutic performance of personalized cancer vaccine via delivery vectors	41
Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids	41
Mucosal drug delivery and 3D printing technologies: A focus on special patient populations	41